ClinicalTrials.gg
RecruitingNCT06767150SAFESTUpdated Dec 31, 2025

StrAtegies For Zoledronic Acid Post-dEnosumab Discontinuation in Postmenopausal oSTeoporosis

A Phase 4 interventional study of a second infusion of ZOL when crosslaps levels reach 300 pg/mL and a rescue second infusion at month-12 (standard traitment) in Postmenopausal Osteoporosis, sponsored by University Hospital, Toulouse. Recruiting at 17 sites in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-31.

Sponsored by University Hospital, Toulouse · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Osteoporosis, Postmenopausal with a site in France — 3 open to participants now, 4 under way, none of them phase 3. Osteoporosis, Postmenopausal · France.

Planned enrollment
15th of 19
200 · median 719
Started
2025
the only one that year
Phase 4
6 of 22
1 open now
Registered
22nd of 22
by date

Among the 22 studies in Osteoporosis, Postmenopausal with a site in France, this one is the 15th largest by planned enrollment of the 19 interventional ones that give a count, is the only one that started in 2025, is one of 6 in phase 4, and was the 22nd registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

3 of the 22 studies in Osteoporosis, Postmenopausal with a site in France are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 20 Osteoporosis, Postmenopausal studies recruiting now, 8 (40%) set no upper age limit and 8 (40%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Osteoporosis, Postmenopausal with a site in France, or all of them as a file.
02

Study summary

Denosumab (Dmab) is a treatment for postmenopausal osteoporosis. However, its withdrawal is associated with a rebound phenomenon associated with an unexpected increased risk of vertebral fractures. Defining the optimal strategy for Dmab withdrawal is critically needed. Investigator propose an open-label randomized superiority strategy trial to compare the 1-year lumbar densitometric efficacy of biomarkers-driven zoledronate (ZOL) infusion vs standardized ZOL treatment to mitigate rebound phenomenon.

Read the detailed description

Denosumab (Dmab) is a potent and validated treatment for postmenopausal osteoporosis. However, its withdrawal, especially after reaching therapeutic target, is associated with a rebound phenomenon characterized by: (i) an increase in bone turnover markers levels usually within first 6 months off-treatment, (ii) a decrease in BMD, and (iii) an unexpected increased risk of (multiple) vertebral fractures. Although current experts' recommendations propose a post-Dmab bisphosphonates therapy (such as ZOL) to mitigate rebound phenomenon, the optimal strategy is still matter of debate. Data suggesting a protective effect with bisphosphonates (1 infusion of ZOL or weekly alendronate) are scarce, with discrepancies, and highlight that a substantial proportion of patients experiences rebound-related bone loss despite bisphosphonate therapy. Crosslaps, a bone turnover maker, are available for daily clinical practice and reflect the antiresorptive activity of anti-resorptive drugs such as bisphosphonates. Investigator hypothesize that monitoring crosslaps levels, can help to identify patients requiring more intensive bisphosphonate (additional ZOL infusion) therapy to control the post-Dmab rebound phenomenon.

Investigator propose to compare 2 strategies for Dmab withdrawal in postmenopausal osteoporosis: a standard treatment control group treated with a single ZOL infusion versus a biomarker-guided ZOL group with an additional ZOL infusion in case of insufficient inhibition of bone resorption according to crosslaps.

03

Conditions studied

  • Postmenopausal Osteoporosis

Keywords

  • Postmenopausal osteoporosis
  • strategy
  • denosumab
  • zoledronate
  • rebound
  • withdrawal
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women with osteoporosis
  • And treated with denosumab for at least 2 years and reaching decision of denosumab withdrawal because of achieved therapeutic target defined as no fracture during treatment; no new risk factors; no BMD decrease > 0.03 g/cm² at the spine or hip;
  • And with a history of severe fracture or a femoral or lumbar T-score ≤ -2.5 prior denosumab initiation.

Exclusion criteria

Exclusion Criteria:

  • Dmab use for bone disease other than osteoporosis.
  • Uncontrolled endocrine diseases. Liver failure.
  • Use of medication affecting bone metabolism during the last year, including bisphosphonates, teriparatide, romosozumab, Selective Estrogen Receptor Modulators, breast cancer hormonotherapy, over 5 mg/day.
  • to bisphosphonates according to license recommendation including chronic kidney disease with stage > or = G3b. Prior intolerance to zoledronic acid.
  • Subjects unable to give an or to fill the case report form. Subjects under law protection.
  • Foreseeable poor compliance with the strategy, alcoholism, toxicomania.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Intensive biomarkers-guided arm

    A second infusion when crosslaps levels reach 300 pg/mL, no later than month-12

    Drug: a second infusion of ZOL when crosslaps levels reach 300 pg/mL

  • Active comparator
    Standard treatment arm

    Potentially a rescue second infusion at month-12, in case unfavourable outcome (incident osteoporotic fractures) or high risk of unfavourable outcome

    Drug: a rescue second infusion at month-12 (standard traitment)

Interventions

  • Druga second infusion of ZOL when crosslaps levels reach 300 pg/mL

    a first infusion of ZOL 5 mg, 6 months after denosumab withdrawal (= study start) and a second infusion when crosslaps levels reach 300 pg/mL, no later than month-12

  • Druga rescue second infusion at month-12 (standard traitment)

    a first infusion of ZOL 5 mg, 6 months after denosumab withdrawal (= study start), and potentially a rescue second infusion at month-12, in case unfavourable outcome (incident osteoporotic fractures) or high risk of unfavourable outcome

06

What researchers measure

Primary outcomes

  1. Maintain lumbar bone mineral density (BMD) after 1 year of ZOL

    The proportion of patients who failed to maintain lumbar BMD after 1 year of ZOL according to the Least Significant Change (LSC) criterion

    Time frame: 1 year after inclusion

Secondary outcomes

  1. Maintain hip bone mineral density (BMD) after 1 year of ZOL

    The proportion of patients who failed to maintain hip BMD after 1 year of ZOL according to the Least Significant Change (LSC) criterion

    Time frame: 1 year after inclusion

  2. the changes in hip and lumbar BMD from baseline

    the changes in hip and lumbar BMD from baseline to 1 year, and from year 1 to year 2 after ZOL, according to the Least Significant Change (LSC) criterion

    Time frame: Day 0, 1 year after inclusion, 2 year after inclusion

  3. the changes from baseline in bone turnover markers

    Bone turnover markers is a composite measure derived from crosslaps, bone alkaline phosphatase, osteocalcin, amino-terminal propeptide of type 1 procollagen, TRAP5b, dickkopf 1, sclerostin

    Time frame: 1 year after inclusion, 2 year after inclusion

  4. morphometric vertebral fractures

    the number of morphometric vertebral fractures measured by vertebral fracture assessment (VFA) or X-rays, of clinical vertebral fractures and of clinical peripheral fractures

    Time frame: 1 year after inclusion, 2 year after inclusion

  5. Patients requiring a second ZOL

    the proportion of patients requiring a second ZOL infusion across groups.

    Time frame: 1 year after inclusion, 2 year after inclusion

  6. Relation between biomarker values and densitometry evolution

    the relation is defined by biomarker values (cross laps) and densitometry evolution measured bu osteodensitometry

    Time frame: 3, 6, 9, 12 months after inclusion

  7. Relation between biomarker values and appearance of new vertebral fracture

    the relation is defined by biomarker values (cross laps) and appearance of new vertebral fracture measured by VFA or X-rays

    Time frame: 3, 6, 9, 12 months after inclusion

07

Study locations

16 of 17 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Oct 2030, 60 months after the start.

Of 27 phase 4 interventional studies under Osteoporosis, Postmenopausal, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 66. This study's planned 60 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2025
First posted
Jan 9, 2025
StartActual
Oct 2, 2025
Primary completionEst.
Oct 2030
CompletionEst.
Oct 2030
Last update
Dec 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06767150
Responsible party
Sponsor
First posted
Jan 9, 2025
Start date
Oct 2, 2025
Primary completion
Oct 2030 (estimated)
Completion
Oct 2030 (estimated)
Last update
Dec 31, 2025

Study contacts

Yannick DEGBOE, MD
Contact
degboe.y@chu-toulouse.fr
05 61 77 73 75 ext. +33
Charline DAGUZAN
Contact
daguzan.c@chu-toulouse.fr
05 61 77 84 90 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion